Carbapenem-Resistant Gram-Negative Bacterial Pulmonary Infections
Conditions
Interventions
Control group: CMS atomization + non-CMS intravenous group:None
Observation group: CMS atomization +CMS intravenous group:None
Sponsors
Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Age =18 years old; 2) Patients who meet the diagnostic criteria for pulmonary infection in the Guidelines for the Diagnosis and Treatment of Chinese Adult Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia (2018 edition); 3) Infection caused by Gram-negative bacteria (CRO) that are determined or strongly suspected to be resistant to carbapenems but sensitive to CMS; 4) CMS is included in the antibiotic regimen; 5) The treatment time of control group and observation group was =3 days; 6) Patients admitted to the center after January 2022 (e.g., January 1, 2022 - February 29, 2024);
Exclusion criteria
Exclusion criteria: 1) Patients with incomplete medical records or missing clinical test indicators, which can not be evaluated for efficacy and safety; 2) Patients who received other polycolistin drugs within 7 days prior to inclusion, and patients who used a combination of polycolistin drugs; 3) The researchers considered that there were other inappropriate enrollment factors (such as confusion in antibiotic use, difficulty in analysis, etc.);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinically effective; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bacterial clearance rate;Case fatality rate at 14/28 days; | — |
Countries
China
Contacts
Public ContactGao Zhancheng
Peking University People's Hospital
Outcome results
None listed